Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study to Compare the Bioavailability and Pharmacokinetics of Cyclosporine After Intravenous Administration of NEUROSTAT, a CREMOPHOR EL-free Lipid Emulsion, and SANDIMMUNE Injection (a Suspension of Cyclosporine in CREMOPHOR EL) in Healthy Volunteers ; An Open-label, Subject-blind, Laboratory-blind, Single-dose (5 mg/kg Infusion), Randomised, Two-period Crossover Tolerability Study Carried Out in Healthy Male and Female Subjects

Trial Profile

A Study to Compare the Bioavailability and Pharmacokinetics of Cyclosporine After Intravenous Administration of NEUROSTAT, a CREMOPHOR EL-free Lipid Emulsion, and SANDIMMUNE Injection (a Suspension of Cyclosporine in CREMOPHOR EL) in Healthy Volunteers ; An Open-label, Subject-blind, Laboratory-blind, Single-dose (5 mg/kg Infusion), Randomised, Two-period Crossover Tolerability Study Carried Out in Healthy Male and Female Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 21 Sep 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ciclosporin (Primary)
  • Indications Amyotrophic lateral sclerosis; Chronic brain damage; Stroke
  • Focus Pharmacokinetics
  • Sponsors Abliva; NeuroVive Pharmaceutical
  • Most Recent Events

    • 20 Sep 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health: NCT01692834).
    • 30 Mar 2010 Primary endpoint 'Drug-bioavailability' has been met.
    • 30 Mar 2010 Status changed from active, no longer recruiting to completed as reported in a Neurovive media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top